Literature DB >> 12589030

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

Paul Workman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12589030

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  30 in total

Review 1.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.

Authors:  Stephanie M Cohen; Ridhwi Mukerji; Abbas K Samadi; Xuan Zhang; Huiping Zhao; Brian S J Blagg; Mark S Cohen
Journal:  Ann Surg Oncol       Date:  2011-08-12       Impact factor: 5.344

Review 3.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 4.  Heat shock proteins as emerging therapeutic targets.

Authors:  Csaba Sõti; Enikõ Nagy; Zoltán Giricz; László Vígh; Péter Csermely; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

5.  The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion.

Authors:  Ellinor Oxelmark; Jennifer M Roth; Peter C Brooks; Steven E Braunstein; Robert J Schneider; Michael J Garabedian
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 6.  Maximum tolerated dose: clinical endpoint for a bygone era?

Authors:  Chris H Takimoto
Journal:  Target Oncol       Date:  2009-04-18       Impact factor: 4.493

Review 7.  Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Authors:  Joaquin Mateo; Michael Ong; David S P Tan; Michael A Gonzalez; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2013-10-15       Impact factor: 66.675

Review 8.  Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors:  Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2021-03-24       Impact factor: 66.675

Review 9.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

10.  Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.

Authors:  H Carl Le; Mihaela Lupu; Khushali Kotedia; Neal Rosen; David Solit; Jason A Koutcher
Journal:  Magn Reson Med       Date:  2009-11       Impact factor: 4.668
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.